Stockholm – October 15, 2026 -- The US National Institutes of Health (NIH) has selected SciBase Holding AB's Nevisense electrical impedance spectroscopy (EIS) technology as the primary endpoint in its THREAT study, which will test how environmental exposures affect the skin barrier in 80 healthy volunteers.

Stockholm – October 14, 2026 -- SciBase Holding AB (STO: SCIB) has received its first positive medical policy for Nevisense from Highmark Blue Cross Blue Shield, which serves more than 7 million members across multiple US states. The decision moves eligible use of the skin-lesion device from a predominantly cash-pay model into covered care through a major private insurer.

Stockholm – October 07, 2026 -- SciBase Holding AB has recalculated the terms of its series TO 2 warrants following a rights issue of shares resolved by its board on September 3, 2026, cutting the subscription ratio to 0.01 shares per warrant.

Stockholm – October 01, 2026 -- SciBase Holding AB has closed its rights issue fully subscribed, raising approximately SEK 57.5 million before issue costs to fund continued commercialisation of its Nevisense melanoma-diagnostics platform in the United States.

Stockholm – September 25, 2026 -- SciBase Holding AB's SEK 57.5 million rights issue is now fully covered after Bergs Securities AB confirmed a binding guarantee commitment of approximately SEK 24.2 million, equal to 42 percent of the offering.

Stockholm – September 17, 2026 -- SciBase Holding AB has pushed back the first day of trading in subscription rights and paid subscribed shares (BTA) tied to its ongoing rights issue by one day, moving the start date from September 15, 2026 to September 16, 2026 on Nasdaq First North Growth Market.

The subscription period itself remains unchanged, running from September 15 through September 29, 2026.